Healthy Yuan Haibin Pharmaceutical

Joincare Haibin Pharmaceutical, also known as Healthyuan Haibin Pharmaceutical, is a leading Chinese pharmaceutical company and a core subsidiary of the Joincare Pharmaceutical Group (Healthy Yuan). Established in 2018 and headquartered in Shenzhen's Pingshan District, the company specializes in the research, development, and large-scale manufacturing of high-barrier complex formulations, particularly inhalation therapies for respiratory diseases. Its commercial portfolio includes Jianketo (tobramycin inhalation solution), the first inhaled antibiotic approved in China for bronchiectasis, alongside a wide range of nebulized solutions and powders for asthma and COPD. The company maintains a robust innovation pipeline featuring Pixavir Marboxil (TG-1000), a late-stage anti-influenza candidate, and several licensed-in programs targeting inflammatory pathways such as TSLP and IL-4Rα. With state-of-the-art GMP-compliant facilities and a strategic focus on respiratory medicine, Joincare Haibin is a dominant player in the domestic inhalation drug market.